Humana Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

Here's Why Investors Should Retain Humana Stock for Now - TradingView

AI-generated analysis

πŸ“ˆ HUM shares have surged 55.7% year-to-date, significantly outpacing the industry's 20.9% growth.

πŸ’° The company beat earnings estimates in each of the past four quarters with an average surprise of 9.6%.

πŸ‘₯ Medicare Advantage membership grew 23.8% year over year in Q2 2026, providing a foundation for improved earnings potential.

πŸ’΅ Total premiums increased 26.4% year over year to $38.8 billion in the second quarter of 2026.

πŸ₯ CenterWell revenues increased 22.6% year over year as the company expands its senior-focused primary care footprint.

🀝 Humana plans to acquire MaxHealth using proceeds from the divestiture of its minority stake in Gentiva, valued at approximately $900 million.

πŸ’» The company is integrating technology and AI into operations to improve efficiency and simplify its business model.

πŸ’° As of June 30, 2026, Humana held cash, equivalents, and investment securities totaling $23.9 billion.

πŸ“‰ Operating expenses rose 26.3% year over year in Q2 2026, reaching 96.7% of revenues due to rising medical cost intensity.

βš–οΈ Humana's total debt-to-capital stands at 43.1%, which exceeds the industry average of 41.5%.

Bullish Signals
  • HUM shares have surged 55.7% year-to-date, significantly outperforming the industry's 20.9% growth.
  • The company beat earnings estimates in each of the past four quarters with an average surprise of 9.6%.
  • Medicare Advantage membership grew 23.8% year over year in Q2 2026, providing a foundation for improved earnings potential.
  • Total premiums increased 26.4% year over year to $38.8 billion in the second quarter of 2026.
  • CenterWell revenues increased 22.6% year over year as the company expands its senior-focused primary care footprint.
  • Humana plans to acquire MaxHealth using proceeds from the divestiture of its minority stake in Gentiva, valued at approximately $900 million.
  • The company is integrating technology and AI into operations to improve efficiency and simplify its business model.
  • As of June 30, 2026, Humana held cash, equivalents, and investment securities totaling $23.9 billion.
Risk Factors
  • Operating expenses rose 26.3% year over year in Q2 2026, reaching 96.7% of revenues due to rising medical cost intensity.
  • Humana's total debt-to-capital stands at 43.1%, which exceeds the industry average of 41.5%.
Full Analysis
Humana Inc. (HUM) is highlighted as a strong hold for investors due to its robust value-based care model, strategic acquisitions, and the tailwinds of an aging U.S. population. The company has significantly outperformed its industry peers, with shares surging 55.7% year-to-date compared to the sector's 20.9% growth. Humana offers comprehensive health insurance through HMO, PPO, and FFS plans, alongside specialty products like dental and vision. Financially, Humana demonstrates strong earnings consistency, beating estimates in four consecutive quarters with an average surprise of 9.6%. Its Medicare Advantage business serves as a primary growth engine, seeing membership expand 23.8% and premiums rise 26.4% year-over-year in the second quarter of 2026. The company is also leveraging its CenterWell subsidiary to integrate pharmacy and home health services, driving a 22.6% revenue increase for that segment. Despite positive momentum, Humana faces headwinds including rising medical cost intensity which increased operating expenses to 96.7% of revenues in Q2 2026. The company carries a debt-laden balance sheet with $12 billion in long-term debt and a forward P/E ratio significantly higher than the industry average. However, Humana maintains a solid financial position with $23.9 billion in cash and investment securities, allowing for continued capital allocation toward growth initiatives and shareholder returns via dividends and buybacks.